

AMENDMENTS TO THE SPECIFICATION

Please insert the following section heading and paragraph on page 1, line 3:

Cross-Reference to Related Applications

The present application is a 35 U.S.C. § 371 National Stage patent application of International patent application PCT/FR03/01234, filed on April 17, 2003, which claims priority to French patent application FR 02/04926, filed on April 19, 2002

Please amend the paragraph beginning on page 9, line 5, as follows:

According to the invention, the CD4 peptide advantageously has the sequence (I) below:

{Cys or *TPA*} - P<sup>1</sup> - Cys - P<sup>2</sup> - Cys - P<sup>3</sup> - Cys - {Ala or Gln} - {Gly or (D)Asp or Ser} - {Ser or His or Asn} - Xaa<sup>J</sup> - Cys - {Thr or Ala} - Cys - Xaa<sup>K</sup> - NH<sub>2</sub>    (SEQ ID NO: 19)

in which *TPA* represents thiopropionic acid, Xaa<sup>J</sup> represents β-naphthylalanine, phenylalanine or biphenylalanine, Xaa<sup>K</sup> represents Gly, Val or Ileu, P<sup>1</sup> represents 3 to 6 amino acids, P<sup>2</sup> represents 2 to 4 amino acids and P<sup>3</sup> represents 6 to 10 amino acids, the amino acids in P<sup>1</sup>, P<sup>2</sup> and P<sup>3</sup> being natural or unnatural, identical or different, and P<sup>1</sup>, P<sup>2</sup> and P<sup>3</sup> possibly having a common sequence, said peptide having a β-hairpin conformation in which the β-turn is made up of the amino acid residues Ala or Gln - Gly or DAsp or Ser-Ser or His or Asn- Xaa<sup>J</sup> of its sequence (A). In fact, these peptides show a very great affinity for the gp120 viral protein.

Please replace the previously filed Sequence Listing with the attached Substitute Sequence Listing beginning on new page 39.